4-Methyloctanoic acid (Standard)
4-Methyloctanoic acid (Standard) is the analytical standard of 4-Methyloctanoic acid (HY-W010178). This product is intended for research and analytical applications. 4-Methyloctanoic acid (Standard) is an endogenous branched-chain medium-chain fatty acid and a negative regulator of the cAMP/PKA signaling pathway. 4-Methyloctanoic acid (Standard) exerts antiepileptic effects by inhibiting epileptiform discharges and terminating behavioral and electroencephalographic seizures. 4-Methyloctanoic acid (Standard) has neuroprotective effects; its polar metabolites can cross the blood-brain barrier, repair presynaptic release defects, improve motor function and alleviate neuromuscular degeneration in ALS models. 4-Methyloctanoic acid (Standard) regulates phosphatidylinositol metabolism, reduces PIP/PIP2 levels and increases inositol levels. 4-Methyloctanoic acid (Standard) can be used in studies related to epilepsy and amyotrophic lateral sclerosis.
For research use only. We do not sell to patients.
- CAS No.: 54947-74-9
- Formula: C9H18O2
- Molecular Weight:158.24
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Purity & Documentation
-
Help & FAQs
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS No. 54947-74-9
-
Molecular Weight 158.24
-
Formula C9H18O2
-
SMILES
CCCCC(C)CCC(O)=O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Chang P, et al. Seizure control by ketogenic diet-associated medium chain fatty acids. Neuropharmacology. 2013;69:105-114. [Content Brief]
[3]. Walker MC, et al. New experimental therapies for status epilepticus in preclinical development. Epilepsy & Behavior. 2015 Aug 1;49:290-3. [Content Brief]
[4]. Nagatsugi F, et al. 18F-labeled octanoates as potential agents for cerebral fatty acid studies. The influence of 4-substitution and the fluorine position on biodistribution. Chem Pharm Bull (Tokyo). 1995 Apr;43(4):607-15. [Content Brief]
[5]. Dunn E, et al. Medium-Chain Fatty Acids Rescue Motor Function and Neuromuscular Junction Degeneration in a Drosophila Model of Amyotrophic Lateral Sclerosis. Cells. 2023;12(17):2163. Published 2023 Aug 28. [Content Brief]
[6]. Chang P, et al. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis Model Mech. 2012;5(1):115-124. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
4-Methyloctanoic acid (Standard) Related Classifications
HY-W010178R Related Classifications
Powered by Bioz
- 4-Methyloctanoic acid (Standard)
- 54947-74-9
- Reference Standards
- Endogenous Metabolite
- PKA
- seizure activity
- phosphatidylinositol bisphosphate
- cAMP/protein kinase A pathway
- epileptiform activity
- epilepsy
- mossy fibre
- phosphatidylinositol monophosphate
- amyotrophic lateral sclerosis
- blood-brain barrier
- inositol
- Inhibitor
- inhibitor
- inhibit